Skip to main content
SpringerLink
Log in

Plasma proteins for therapeutic use: past, present and future

  • Chapter
Supportive therapy in haematology

  • 98 Accesses

Abstract

The development and clinical use of plasma proteins has a history of sporadic quantum jumps coupled with years of stagnation. The quantum jumps occur with the development of new technology, whereas the stagnation occurs when there is unimaginative management of the plasma resource and lack of funding for new product development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohn EJ, Strong LE, Hughes WL Jr, Mulford DJ, Ashworth JN, Melin M, Taylor HL: Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc, 1946; 68: 459–75.

    Article  PubMed  CAS  Google Scholar 

  2. Bering EA Jr: Chemical, clinical, and immunological studies on the products of human plasma fractionation. XX. The development of fibrin foam as a hemostatic agent and for use in conjunction with human thrombin. J Clin Invest, 1944; 23: 586–90.

    Article  PubMed  CAS  Google Scholar 

  3. Bove JR: Fibrinogen — is the benefit worth the risk? Transfusion, 1978; 18: 129–36.

    Article  PubMed  CAS  Google Scholar 

  4. Alexander B, Landwehr G: Studies of hemophilia. II. The assay of the antihemophilic clot-promoting principle in normal human plasma with some observations on the relative potency of certain plasma fractions. J Clin Invest, 1948; 27: 98–105.

    Article  CAS  Google Scholar 

  5. Melin M, Jansky JW, Leonardos G, Di Francesco A, Pennell RB, Tullis JL: The preparation of a prothrombincontaining fraction from human plasma by chromatography. Vox Sang, 1964; 9: 227 (abstract).

    Article  CAS  Google Scholar 

  6. Curling JM (ed): Methods of Plasma Protein Fractionation. Academic Press, New York, 1980.

    Google Scholar 

  7. Choo KH, Gould KG, Rees DJG, Brownlee GG: Molecular cloning of the gene for human anti-haemophilic factor IX. Nature, 1982; 299: 178–80.

    Article  PubMed  CAS  Google Scholar 

  8. Chandra T, Kurachi K, Davie EW, Woo SLC: Induction of a1-antitrypsin mRNA and cloning of its cDNA. Biochem Biophys Res Commun, 1981; 103: 751–58.

    Article  PubMed  CAS  Google Scholar 

  9. Suggs SV, Wallace RB, Hirose T, Kawashima EH, Itakura K: Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human (32-microglobulin. Proc Natl Acad Sci USA, 1981; 78: 6613–17.

    Article  PubMed  CAS  Google Scholar 

  10. Lawn RM, Adelman J, Bock SC, Franke AE, Houck CM, Najarian RC, Seeburg PH, Wion KL: The sequence of human serum albumin cDNA and its expression in E. coli. Nucleic Acids Res, 1981; 9: 6103–14.

    Article  CAS  Google Scholar 

  11. Ricca GA, Hamilton RW, McLean JW, Conn A, Kalinyak JE, Taylor JM: Rat ai-acid glycoprotein mRNA. Cloning of double-stranded eDNA and kinetics of induction of mRNA levels following acute inflammation. J Biol Chem, 1981; 256: 10362–68.

    PubMed  CAS  Google Scholar 

  12. Crabtree GR, Kant JA: Molecular cloning of eDNA for the α, β, and γ chains of rat fibrinogen. A family of coordinately regulated genes. J Biol Chem, 1981; 256: 9718–23.

    PubMed  CAS  Google Scholar 

  13. Odink KG, Fey G, Wiebauer K, Diggelmann H: Mouse complement components C3 and C4. Characterization of their messenger RNA and molecular cloning of complementary DNA for C3. J Biol Chem, 1981; 256: 1453–58.

    PubMed  CAS  Google Scholar 

  14. Prochownik EV, Orkin SH: Isolation of the human anti-thrombin III gene. Blood, 1982; 60 (suppl. 1): 806 (abstract).

    Google Scholar 

  15. Sinkovics JG, Dreesman GR: Monoclonal antibodies of hybridomas. Rev Infect Dis, 1983; 5: 9–34.

    Article  PubMed  CAS  Google Scholar 

  16. Gadek JE, Hosea SW, Gelfand JA, Santaella M, Wickerhauser M, Triantaphyllopoulos DC, Frank MM: Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified Cl inhibitor. N Engl J Med, 1980; 302: 542–46.

    Article  PubMed  CAS  Google Scholar 

  17. Gadek JE, Klein HG, Holland PV, Crystal RG: Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest, 1981; 68: 1158–65.

    Article  PubMed  CAS  Google Scholar 

  18. Skillman JJ: Use of colloid in massive transfusions. In: Massive Transfusion in Surgery and Trauma, Collins JA, Murawski K, Shafer AW (eds). Alan R. Liss, New York, 1982: 65–68.

    Google Scholar 

  19. Smith T: Active immunity produced by so-called balanced or neutral mixtures of diphtheria toxin and antitoxin. J Exp Med, 1909; 11: 241–56.

    Article  PubMed  CAS  Google Scholar 

  20. Finn R, Clarke CA, Donohoe WTA, McConnell RB, Sheppard PM, Lehane D, Kulke W: Experimental studies on the prevention of Rh haemolytic disease. Br Med J, 1961; 1: 1486–90.

    Article  PubMed  CAS  Google Scholar 

  21. Pollack W, Gorman JG, Hager HJ, Freda VJ, Tripodi D: Antibody-mediated immune suppression to the Rh factor: animal models suggesting mechanism of action. Transfusion, 1968; 8: 134–45.

    Article  PubMed  CAS  Google Scholar 

  22. Freda VJ, Gorman JG, Pollack W: Rh Factor: prevention of isoimmunization and clinical trial on mothers. Science, 1966; 151: 828–30.

    Article  PubMed  CAS  Google Scholar 

  23. Chedid L, Parant M, Parant F, Boyer F: A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol, 1968; 100: 292–301.

    PubMed  CAS  Google Scholar 

  24. Braude AI, Douglas H: Passive immunization against the local Shwartzman reaction. J Immunol, 1972; 108: 505–12.

    PubMed  CAS  Google Scholar 

  25. Braude AI, Douglas H, Davis CE: Treatment and prevention of intravascular coagulation with antiserum to endotoxin. J Infect Dis, 1973; 128: S157–64.

    Article  Google Scholar 

  26. Ziegler EJ, Douglas H, Sherman JE, Davis CE, Braude AI: Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-Gal epimerase-deficient mutant. J Immunol, 1973; 111: 433–38.

    CAS  Google Scholar 

  27. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coll. N Engl J Med, 1982; 307: 1225–30.

    Article  PubMed  CAS  Google Scholar 

  28. Wyke RJ, Tsiquaye KN, Thornton A, White Y, Portmann B, Das PK, Zuckerman AJ, Williams R: Transmission of non-A non-B hepatitis to chimpanzees by factor-IX concentrates after fatal complications in patients with chronic liver disease. Lancet, 1979; 1: 520–24.

    Article  PubMed  CAS  Google Scholar 

  29. Sugg U, Schnaidt M, Schneider W, Lissner R: Clotting factors and non-A, non-B hepatitis. N Engl J Med, 1980; 303: 943.

    PubMed  CAS  Google Scholar 

  30. Gellis SS, Neefe JR, Stokes J Jr, Strong LE, Janeway CA, Scatchard G: Chemical, clinical, and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest, 1948; 27: 239–44.

    Article  Google Scholar 

  31. Scatchard G, Gibson ST, Woodruff LM, Batchelder AC, Brown A: Chemical, clinical, and immunological studies on the products of human plasma fractionation. IV. A study of the thermal stability of human serum albumin. J Clin Invest, 1944; 23: 445–53.

    Article  PubMed  CAS  Google Scholar 

  32. Heimburger N, Schwinn H, Gratz P, Lüben G, Kumpe G, Herchenhan B: Faktor VIII-Konzentrat, hochgereinigt and in Lösung erhitzt. Arzneim-Forsch, 1981; 31: 619–22.

    CAS  Google Scholar 

  33. Fernandes PM, Lundblad JL: Pasteurized therapeutically active protein compositions. Eur Pat Appl, 1980; 35: 204.

    Google Scholar 

  34. Dolana G, Tse D, Thomas W, Kingdon HS: Hepatitis risk reduction in hemophilia; a heated factor VIII preparation. Blood, 1982; 60: (suppl. 1), 768 (abstract).

    Google Scholar 

  35. Tabor E, Aronson DL, Gerety RJ: Removal of hepatitisB-virus infectivity from factor-IX complex by hepatitis-B immuneglobulin. Lancet, 1980; 2: 68–70.

    Article  PubMed  CAS  Google Scholar 

  36. Brummelhuis HGJ, Over J, Duivis-Vorst CC, Wilson-de Sturler LA, Ates G, Hoek PJ, Reerink-Brongers EE: Contribution to the optimal use of human blood. IX. Elimination of hepatitis B transmission by (potentially) infectious plasma derivatives. Vox Sang, 1983; 45: 205–16.

    Article  PubMed  CAS  Google Scholar 

  37. Prince AM, Stephan W, Brotman B: ß-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives. Rev Infect Dis, 1983; 5: 92–107.

    Article  PubMed  CAS  Google Scholar 

  38. Prince AM, Stephan W, Brotman B, van den Ende MC: Evaluation of the effect of betapropiolactone/ultraviolet irradiation (BPL/UV) treatment of source plasma on hepatitis transmission by factor IX complex in chimpanzees. Thromb Haemost, 1980; 44: 138–42.

    PubMed  CAS  Google Scholar 

  39. Newman J, Johnson AJ, Karpatkin MH, Puszkin S: Methods for the production of clinically effective intermediate-and high-purity factor-VIII concentrates. Br J Haematol, 1971; 21: 1–20.

    Article  PubMed  CAS  Google Scholar 

  40. Weinstein M, Deykin D: Comparison of factor VIII-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate. Blood, 1979; 53: 1095–1105.

    PubMed  CAS  Google Scholar 

  41. Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D: Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med, 1980; 303: 1318–22.

    Article  PubMed  CAS  Google Scholar 

  42. Kasper CK: Thromboembolic complications. Thromb Diath Haemorrh, 1975; 33: 640–44.

    PubMed  CAS  Google Scholar 

  43. Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL: Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh, 1975; 33: 617–31.

    PubMed  CAS  Google Scholar 

  44. Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG: The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood, 1982; 59: 401–7.

    PubMed  CAS  Google Scholar 

  45. Magner A, Aronson DL: Toxicity of factor IX concentrates in mice. Develop Biol Stand, 1979; 44: 185–88.

    CAS  Google Scholar 

  46. Dike GWR, Griffiths D, Bidwell E, Snape TJ, Rizza CR: A factor VII concentrate for therapeutic use. Br J Haematol, 1980; 45: 107–18.

    Article  PubMed  CAS  Google Scholar 

  47. Kosow DP, Behre HE, Orthner CL, Menache D: Preparation and properties of a factor IX concentrate depleted of prothrombin and factor X. Thromb Haemost, 1983; 50: 116 (abstract).

    Google Scholar 

  48. Hultin MB: Activated clotting factors in factor IX concentrates. Blood, 1979; 54: 1028–38.

    PubMed  CAS  Google Scholar 

  49. Seligsohn U, Kasper CK, Osterud B, Rapaport SI: Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood, 1979; 53: 828–37.

    PubMed  CAS  Google Scholar 

  50. Sjamsoedin UM, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sixma JJ: The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med, 1981; 305: 717–21.

    Article  PubMed  CAS  Google Scholar 

  51. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM and the hemophilia study group: Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. A multicenter therapeutic trial. N Engl J Med, 1980; 303: 421–25.

    Article  PubMed  CAS  Google Scholar 

  52. Stenflo J: A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem, 1976; 251: 355–63.

    PubMed  CAS  Google Scholar 

  53. Kisiel W: Human plasma protein C. Isolation, characterization, and mechanism of activation by α-thrombin. J Clin Invest, 1979; 64: 761–69.

    Article  PubMed  CAS  Google Scholar 

  54. Opie EL, Barker BI: Leucoprotease and anti-leucoprotease of mammals and of birds. J Exp Med, 1907; 9: 20721.

    Google Scholar 

  55. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M: Congenital deficiency of α2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest, 1979; 63: 877–84.

    Article  PubMed  CAS  Google Scholar 

  56. Sharp HL, Bridges RA, Krivit W, Freier EF: Cirrhosis associated with alpha-l-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med, 1969; 73: 934–39.

    PubMed  CAS  Google Scholar 

  57. Laurell CB, Eriksson S: The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest, 1963; 15: 132–40.

    CAS  Google Scholar 

  58. Vogelaar EF, Brummelhuis HGJ, Krijnen HW: Contributions to the optimal use of human blood. III. Large-scale preparation of human Cl esterase inhibitor concentrate for clinical use. Vox Sang, 1974; 26: 118–27.

    Article  PubMed  CAS  Google Scholar 

  59. van der Starre P, Sinclair D, Damen J, Brummelhuis H: Inhibition of the hypotensive effect of plasma protein solutions by C1esterase inhibitor. J Thorac Cardiovasc Surg, 1980; 79: 738–40.

    PubMed  Google Scholar 

  60. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh, 1965; 13: 516–30.

    PubMed  CAS  Google Scholar 

  61. Thaler E, Lechner K: Antithrombin III and thromboembolism. Clin Haematol, 1981; 10: 369–90.

    PubMed  CAS  Google Scholar 

  62. Mannucci PM, Boyer C, Wolf M, Tripodi A, Larrieu MJ: Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol, 1982; 50: 531–35.

    Article  PubMed  CAS  Google Scholar 

  63. Brandt P: Observations during the treatment of antithrombin-III deficient women with heparin and antithrombin concentrate during pregnancy, parturition, and abortion. Thromb Res, 1981; 22: 15–24.

    Article  PubMed  CAS  Google Scholar 

  64. Jespersen J, Rasmussen NR, Toftgaard C: Observations during the treatment with antithrombin-III concentrate of a case of tampon-related toxic shock syndrome and disseminated intravascular coagulation. Discrepancies between functional and immunologic determinations of antithrombin. Thromb Res, 1982; 26: 457–62.

    Article  PubMed  CAS  Google Scholar 

  65. Laursen B, Mortensen JZ, Frost L, Hansen KB: Disseminated intravascular coagulation in hepatic failure treated with antithrombin III. Thromb Res, 1981; 22: 701–4.

    Article  PubMed  CAS  Google Scholar 

  66. Schipper HG, ten Cate JW: Antithrombin III transfusion in patients with hepatic cirrhosis. Br J Haematol, 1982; 52: 25–33.

    Article  PubMed  CAS  Google Scholar 

  67. Blauhut B, Necek S, Vinazzer H, Bergmann H: Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res, 1982; 27: 271–78.

    Article  PubMed  CAS  Google Scholar 

  68. Haak HL, Stolk JC, Gratama JW, van Hulsteyn H, Briet E: Use of antithrombin III concentrate in stable diffuse intravascular coagulation. A case report. Acta Haematol, 1982; 68: 28–33.

    Article  PubMed  CAS  Google Scholar 

  69. Kakkar VV: The clinical use of anti-thrombin III. Thromb Haemost, 1979; 42: 265 (abstract).

    Google Scholar 

  70. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE Jr, Mozen MM, Finlayson JS: Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med, 1978; 299: 66–70.

    Article  PubMed  CAS  Google Scholar 

  71. Heinonen J, Peltola K, Himberg JJ, Suomela H: Correlation of hypotensive effect of plasma protein fraction with prekallikrein activator activity: a clinical study in patients having openheart surgery. Ann Thorac Surg, 1982; 33: 24449.

    Article  Google Scholar 

  72. van Rosevelt RF, Bakker JC, Sinclair DM, Damen J, van Mourik JA: Bradykinin-mediated hypotension after infusion of plasma-protein fraction. J Lab Clin Med, 1982; 100: 288–95.

    PubMed  Google Scholar 

  73. Finlayson JS: Albumin products. Sem Thromb Hemost, 1980; 6: 85–120.

    Article  CAS  Google Scholar 

  74. Finlayson JS: Immune globulins. Sem Thromb Hemost, 1979; 6: 44–74.

    Article  CAS  Google Scholar 

  75. Bowman JM, Chown B, Lewis M, Pollock JM: Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J, 1978; 118: 623–27.

    PubMed  CAS  Google Scholar 

  76. Beasley RP, Hwang LY, Lin CC, Stevens CE, Wang KY, Sun TS, Hsieh FJ, Szmuness W: Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet, 1981; 2: 388–93.

    Article  PubMed  CAS  Google Scholar 

  77. Finlayson JS: Immune globulins with special reference to their role in bacterial and viral infections. In: Medical Microbiology, vol 1., Easmon CSF, Jeljaszewicz J (eds). Academic Press, London, 1982: 129–82.

    Google Scholar 

  78. Schultze HE, Schwick G: Über neue Möglichkeiten intravenöser Gammaglobulin-Applikation. Dtsch Med Wschr, 1962; 87: 1643–50.

    Article  PubMed  CAS  Google Scholar 

  79. Alving BM, Finlayson JS (eds): Immunglobulins: Characteristics and Uses of Intravenous Preparations. DHHS Publication No. (FDA)-80–9005, U.S. Government Printing Office, Washington, 1980.

    Google Scholar 

  80. Römer J, Morgenthaler JJ, Scherz R, Skvaril F: Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang, 1982; 42: 62–73.

    PubMed  Google Scholar 

  81. Nolte MT, Pirofsky B, Gerritz GA, Golding B: Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol, 1979; 36: 237–43.

    PubMed  CAS  Google Scholar 

  82. Ammann AJ, Ashman RF, Buckley RH, Hardie WR, Krantmann HJ, Nelson J, Ochs H, Stiehm ER, Tiller T, Wara DW, Wedgwood R: Use of intravenous γ-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol, 1982; 22: 60–67.

    Article  PubMed  CAS  Google Scholar 

  83. Cunningham-Rundles C, Smithwick EM, Siegal FP, Day NK, Cunningham-Rundles S, Koziner B, Lion A, Barandun S, O’Malley J, Good RA: Treatment of primary humoral immunodeficiency disease with intravenous (pH 4.0 treated) gammaglobulin. In: Immunohemotherapy. A Guide to Immunoglobulin Prophylaxis and Therapy, Nydegger UE (ed). Academic Press, London, 1981: 283–90.

    Google Scholar 

  84. Duswald KH, Müller K, Seifert J, Ring J: Wirksamkeit von i.v. Gammaglobulin gegen bakterielle Infektionen chirurgischer Patienten. Ergebnisse einer kontrollierten, randomisierten klinischen Studie. Munch Med Wschr, 1980; 122: 832–36.

    CAS  Google Scholar 

  85. Kornhuber B: Administration of intravenous immunoglobulin to children with malignant diseases. In: Immunoglobulins: Characteristics and Uses of Intravenous Preparations, Alving BM, Finlayson JS (eds). DHHS Publication No. (FDA)-80–9005, U.S. Government Printing Office, Washington, 1980: 107–10.

    Google Scholar 

  86. Condie RM, Hall BL, Howard RJ, Fryd D, Simmons RL, Najarian JS: Treatment of life-threatening infections in renal transplant recipients with high-dose intravenous human IgG. Transplant Proc, 1979; 11: 66–68.

    PubMed  CAS  Google Scholar 

  87. Winston DJ, Ho WG, Rasmussen LE, Lin CH, Chu CL, Merigan TC, Gale RP: Use of intravenous immune globulin in patients receiving bone marrow transplants. J Clin Immunol, 1982; 2: 42S - 47S.

    Article  PubMed  CAS  Google Scholar 

  88. Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet, 1981; 1: 1228–31.

    Article  PubMed  CAS  Google Scholar 

  89. Fehr J, Hofmann V, Kappeler U: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med, 1982; 306: 1254–58.

    Article  PubMed  CAS  Google Scholar 

  90. Pirofsky B: Which is the factual basis, in theory and clinical practice, for the use of intravenous gammaglobulin in the treatment of severe bacterial infections? Vox Sang, 1979; 37: 126–28.

    Google Scholar 

  91. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975; 256: 495–97.

    Article  PubMed  Google Scholar 

  92. Olsson L, Kaplan HS: Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci USA, 1980; 77: 5429–31.

    Article  PubMed  CAS  Google Scholar 

  93. Croce CM, Linnenbach A, Hall W, Steplewski Z, Koprowski H: Production of human hybridomas secreting antibodies to measles virus. Nature, 1980; 288: 488–89.

    Article  PubMed  CAS  Google Scholar 

  94. Smith TW, Butler VP Jr, Haber E, Fozzard H, Marcus FI, Bremner WF, Schulman IC, Phillips A: Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Experience in 26 cases. N Engl J Med, 1982; 307: 1357–62.

    Article  PubMed  CAS  Google Scholar 

  95. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med, 1982; 306: 517–22.

    Article  PubMed  CAS  Google Scholar 

  96. Cohen S, Pick E, Oppenheim JJ (eds): Biology of the Lymphokines. Academic Press, New York, 1979.

    Google Scholar 

Download references

Authors
  1. D. L. Aronson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Finlayson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank, Groningen-Drenthe, The Netherlands

    P. C. Das  & C. Th. Smit Sibinga  & 

  2. Dept. of Haematology, University Hospital, Groningen, The Netherlands

    M. R. Halie

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishers. Boston/Dordrecht/Lancaster

About this chapter

Cite this chapter

Aronson, D.L., Finlayson, J.S. (1985). Plasma proteins for therapeutic use: past, present and future. In: Das, P.C., Sibinga, C.T.S., Halie, M.R. (eds) Supportive therapy in haematology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2577-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2577-2_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9617-1

  • Online ISBN: 978-1-4613-2577-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation